Posted by Michael Wonder on 20 Feb 2024
Omnix Medical granted fast track designation by US FDA for its next generation anti-infective OMN6
20 February 2024 - Omnix Medical today announced that the Company has received fast track designation for its novel anti-infective OMN6 from the US FDA.
OMN6 is Omnix Medical´s lead compound and a novel, first in class antimicrobial peptide based on insect host defense peptides.
